Merck Yesterday Announced KEYTRUDA plus LENVIMA Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
Benzinga Newsdesk